Medix Biochemica Appoints Petra Furu As Chief Executive Officer To Lead Next Growth Phase

Medix Biochemica has announced the appointment of Petra Furu as Chief Executive Officer, effective June 1, 2026. The move marks the completion of a leadership transition phase for the company, which operates as a key supplier to the in vitro diagnostics (IVD) industry.

“Since joining us in June 2025, Petra Furu has already made a significant contribution to Medix Biochemica and demonstrated energetic, people-centered leadership and a strong customer focus throughout. She brings to the CEO role a rare combination of scientific and industry expertise, strategic insight, and the ability to translate strategy into action and business results. The Board is delighted to appoint Petra as CEO and is confident in her ability to lead the company successfully toward its strategic goals,” says Ann-Christine Sundell, the Chair of the Board of Medix Biochemica.

Furu joined Medix Biochemica in June 2025 as Vice President of the Immunoassay Business Unit and brings nearly 20 years of leadership experience in the IVD sector. Prior to this, she held senior roles at Revvity, where she most recently led the reproductive health business. She holds a PhD in Biochemistry along with an executive MBA, strengthening her profile as a science-driven business leader.

“I am honored by the opportunity to lead Medix Biochemica through the next phase of its transformational journey and drive execution of our four must-win battles to achieve our strategic ambitions. While success will require customer centricity in every decision, focused execution, and close collaboration across the organization, I have great confidence in our people, in the commitment and can-do attitude across Medix Biochemica, and in the path we are on,” says Petra Furu, the incoming CEO of Medix Biochemica.

Her appointment follows a transitional period during which Teemu Alahuhta served as interim CEO after the departure of Steve Ferguson in April 2025. The leadership change aligns with the company’s broader strategic evolution.

“I would like to thank the Leadership Team and the entire organization for their drive, commitment, and excellent collaboration throughout the interim CEO period. I am delighted that Petra Furu has been appointed CEO. She is an excellent choice for the role, and her appointment ensures strong continuity in the company’s leadership and the execution of our growth strategy. I wish her every success in the role,” says Teemu Alahuhta, the Vice Chair of the Board of Directors and outgoing interim CEO of Medix Biochemica.

Over the past year, Medix Biochemica has outlined a new growth strategy focused on customer-centric innovation, high-performance solutions, expansion into high-growth markets, and operational excellence. Under Furu’s leadership, the company aims to execute this strategy and drive its next phase of global growth.